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Abstract
Objective: This study evaluated the impact of an Internet-based telematic system on the economic and clinical
management of patients with type 1 diabetes mellitus.
Research Design and Methods: This 6-month prospective, randomized, comparative, open, multicenter study
included patients with type 1 diabetes >18 years old treated with multiple insulin doses and with a glycated
hemoglobin (HbA1c) level of >8%. We compared an intervention group (IG) (two face-to-face and five
telematic appointments) with a control group (CG) (seven face-to-face appointments). The variables studied
were (1) patient and healthcare team costs, (2) metabolic control, (3) knowledge of diabetes, (4) quality of life,
and (5) self-care treatment adherence.
Results: Of the 154 patients included, 118 (76.6%) completed the study (IG, 54; CG, 64). The time used by the
CG to follow the program was 823 – 645 min versus 353 – 222 min in the IG (P < 0.0001). Compared with the
CG, the IG required less healthcare time from the professionals (288 – 105 min vs. 232 – 89 min; P < 0.001).
HbA1c improved in both groups (IG, 9.2 – 1.5% [77.0 – 17.0 mmol/mol] vs. 8.7 – 1.5% [71.6 – 17.0 mmol/mol]
[P < 0.001]; CG, 9.2 – 0.9% [77.0 – 10.0 mmol/mol] vs. 8.6 – 0.9% [70.5 – 10.0 mmol/mol] [P < 0.001], as did
knowledge and self-care treatment adherence.
Conclusions: The use of interactive telematic appointments in subjects with type 1 diabetes and inadequate
metabolic control is an efficient strategy, providing results comparable to those of face-to-face appointments in
relation to improvement in glycemic control, knowledge acquisition, and self-care treatment adherence, with a
significant reduction in the time used, especially by patients.
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T ight glycemic control and intensive support are es-sential for the prevention of acute events and the mini-
mization of long-term complications in type 1 diabetes.1–3 In
order to achieve this objective, a clinical visit is re-
commended every 3 months,4 after having received adequate
diabetes self-management education. However, as patients
are progressively leading a more complex and integrated
professional lifestyle and because of the current shortage of
professional and economic resources, this is not always
possible in real practice. Thus, the challenge is to find alter-
native methods to monitor metabolic control within the
context of an overstressed healthcare system.
Because self-management and computer-aided algorithms
still seem to remain far from widespread implementation,5,6
telemedicine intervention in diabetes and providing moni-
toring (including educational and therapeutic services) could
be a possible alternative to face-to-face outpatient appoint-
ments.7–10 Recently, several devices have incorporated
through interfaces allowing more comprehensive management
of the data for both the patient and the physician.11 Such ad-
vances have been reported to improve fitting insulin needs to
supply, but the effectiveness of such devices has yet to be
tested.12 As these data become more available, new patient–
physician communication channels are being tested. None-
theless, it must be determined whether these new technologies
provide benefits in glucose management, resource saving,
or both.13 Therefore, it is crucial to determine the cost-
effectiveness of this alternative.14 Along this line, it is im-
portant to point out that no favorable impact on glycated he-
moglobin (HbA1c) has been described to date in any study
15,16
and that the data related to costs, albeit positive, are very scarce
and limited to single-center studies.17,18 There are few multi-
center studies,19 and some have not shown any savings.20
In this context, the objective of this study was to estimate
the impact on costs of an Internet-based telemedicine system
replacing clinic visits in a program designed to improve
metabolic control in patients with type 1 diabetes.
Research Design and Methods
Participants
The inclusion criteria included having been diagnosed
with type 1 diabetes at least 5 years previously, 18–55 years
of age, multiple insulin doses, poor glycemic control with
HbA1c level of >8%, performing an average of at least three
blood glucose tests per day, and having Internet access at
home. The exclusion criteria included any contraindication to
tight glycemic control, plans to become pregnant or preg-
nancy, psychiatric disorders, and lack of appointment com-
pliance. All the patients provided written informed consent,
and the Ethics Committee of each participating hospital ap-
proved the study.
Trial design and procedures
We performed a randomized 6-month, open-label, parallel-
group study involving five hospitals in Spain. Prior to the trial,
a blinded computer-based nonclustered (by center) pre-
specified randomization list was created. After inclusion of
subjects, physicians allocated patients to either group after
calling a centralized number. Patients were invited to partici-
pate on attending routine clinical outpatient appointments.
Eligible participants were evaluated in order to ensure ade-
quate diabetes self-management education. On the first visit
(V1) the patients were electronically randomized to either the
control group (CG) or the intervention group (IG). The patients
in the IG were trained in the telematic system. The program
included six monthly visits (V2–V7) in both groups. In the IG
five visits were telematic, and the last visit (V7) was in the
hospital setting. In the CG all the visits were at the hospital.
Participants were asked to carry out at least three self-moni-
toring of blood glucose tests per day, using the same meter
(Glucocard G + meter; provided by Menarini Diagnostics,
Firenze, Italy). In both groups blood glucose control, insulin
doses, mild hypoglycemia (in the last 2 weeks), and severe
hypoglycemia (in the last 6 months) were evaluated in order to
define the most appropriate times of blood glucose monitoring,
optimization of basal and short-acting insulin doses, and ad-
justment of insulin with food and physical activity. At every
visit, patients were asked to recall if they needed extra medical/
paramedical interventions, and details were obtained on the
time and costs of each visit.
Patients allocated to the IG were instructed in the man-
agement of the Medical Guard Diabetes (MGD) system
(Pulso Ediciones, Barcelona, Spain) and were asked to report
the data once a month. A response from their diabetes team
was then expected within the following 3 days with recom-
mendations on treatment adjustments. Access to the MGD
system was granted at the time of randomization.
Data from the CG were obtained on-site during the visit
and were then transferred to an electronic database, whereas
subjects in the IG filled in a predefined electronic question-
naire. Investigators could know whether patients had com-
pleted the questionnaires and send reminders when needed.
MGD system
The MGD system is an Internet-based telemedicine system
that allows automatic downloading of the self-monitoring of
blood glucose values to a secure Web site (www.medi-
calguard.net) where the data are available to investigators at
any time. Additionally, the patient may introduce changes in
the insulin doses, diet, or exercise, as well as make comments
in a text message of < 500 words. The MGD is a system
compatible with several meters (those from Abbott Labora-
tories [Abbott Park, IL], Bayer Hispania SL [Barcelona],
Johnson & Johnson SA [Zug, Switzerland], and Menarini
Diagnostics SA). The system has different types of presen-
tations of glucose values, including the standard day, linear
graph, histogram, and .pdf report. In addition, the insulin and
carbohydrate schedule could be seen.
Patients in the IG were provided with an interface PC-
meter and the specific software.
Outcome measures
Costs. To analyze the patient costs per each type of
telematic or hospital appointment, we determined the overall
time spent in each visit, the direct transport payments, and the
need for extra visits (or telephone consultations). On each
clinical or telematic appointment, patients and professionals
were asked to answer a specifically designed costs ques-
tionnaire. The medical team costs included time spent on
both types of appointments.






















































The time costs for patients were also accounted for con-
sidering the time devoted to each visit (home-based or hospital-
based) and adjusted for professional role and job category
(unemployed, household workers, students, noncertified ser-
vice workers, certified workers, bachelors degree, or other).
According to the Spanish Instituto Nacional de Estadistica,
time-cost adjustments were made considering the average
national salary (for Spain in 2012) for each of the categories
described. Similar to other studies,17 in the time costs for
healthcare professionals we attributed 75% of the time con-
sumed to the nurse and 25% to the physician (with the average
nurse’s wage = 24 e/h and the average doctor’s wage = 48e/h).
For transportation costs, we took the mean value of the dif-
ferent ranges provided in the per-visit questionnaires.
Extra visits were also recorded, and if needed, a cost of
120 e per visit was considered, according to the tariffs of the
Spanish Health System.
Clinical evolution. The effectiveness of the intervention
was monitored by HbA1c as well as the number of hypogly-
cemia events (mild or severe), acute complications of dia-
betes, and adherence to treatment. After glycemia charts were
reviewed, a comprehensive clinical evaluation was per-
formed at each visit to assess changes in diet and insulin
regimens. HbA1c was measured by high-performance liquid
chromatography (Menarini Diagnostics).
1. Hypoglycemia. Hypoglycemic episodes were obtained
from logbooks and the memory of the glucose meters.
Mild events were defined as signs or symptoms asso-
ciated with hypoglycemia experienced by the patient
and self-treated without the need for assistance from a
third party or a blood glucose level of <3.3 mmol/L.
Severe hypoglycemic events (those associated with
neuroglycopenia severe enough to require treatment
from a third party) and severe hyperglycemic events
(requiring medical consultation) and ketoacidosis were
considered as the number of events per patient during
the study.
2. Quality of life. Quality of life was measured by the
disease-specific Spanish Diabetes Quality of Life test,
which has four scales: satisfaction (minimum score 15,
maximum score 75), impact (minimum score 17, max-
imum score 85), social worry (minimum score 7, max-
imum score 35), and diabetes worry (minimum score 4,
maximum score 20), with a lower score indicating better
perception21,22 and with the generic visual analog scale
of the European Quality of Life test.23
3. Diabetes self-management. Diabetes self-management
was evaluated by blood glucose testing frequency, and
insulin modification was determined from the log-
books and the meter downloads for each patient, as
well as the Diabetes Knowledge Questionnaire24
adapted to Spanish, adherence to self-care with the
Diabetes Self-Care Inventory—Revised,25 and hypo-
glycemia perception with the Clarke test.26
Power calculation and statistical analysis
The study was powered to detect a cost change in the IG
(b = 0.05, a = 0.05). To detect a 20% difference in the costs at
6 months, 72 patients were needed in each group to achieve a
statistical power of 95% with a 5% two-sided a level.17,18 We
aimed to recruit 154 patients, allowing for a 10% dropout rate
(STATA version 11; StataCorp, College Station, TX).
Data are expressed as mean – SD values or as a percentage.
Changes from baseline values at the end of the study were
compared with a paired t test. The mean values were com-
pared using the t test for paired and nonpaired variables,
assuming, according to Altman and Bland,27 that the
boundaries between parametric and rank methods are not
clear. A P value of < 0.05 was considered statistically sig-
nificant. All statistical calculations were performed with
Statistical Package for Social Science (SPSS) for personal
computers version 21.0.0 software (SPSS, Inc., Chicago, IL).
Results
Patient population
In total, 162 patients were invited to participate, 154 of
whom were subsequently assessed and randomized from
May 2011 to October 2011. Seventy-eight patients were as-
signed to the IG, and 76 were allocated to the CG. There were
no remarkable differences at baseline between the two groups
in regard to demographic and clinical characteristics (Table 1).
After 6 months of follow-up, 36 patients had dropped out of the
study (24 in the IG and 12 in CG, with a statistical power of
85% remaining) because of noncompliance with the protocol,
connection problems, accident, or suicide attempt (Fig. 1). At
2, 4, and 6 months, there were eight, two, and two patients lost
to follow-up in the CG and 15, seven, and two in the IG,
respectively. There were no differences in the baseline char-
acteristics of the patients who dropped out of the study.
Costs
In relation to patients who finished the study, the mean
total time spent by the patients in the IG in the follow-up
Table 1. Demographic and Baseline Characteristics





Number of subjects 76 78
Baseline HbA1c
% 9.2 – 0.9 9.3 – 1.5 0.372
mmol/mol 77 – 13.6 78 – 7.1
Age (years) 31.5 – 9.0 32.2 – 10.1 0.650
Female sex (%) 52.6 57.6 0.269
BMI (kg/m2) 24.9 – 4.3 25.6 – 4.1 0.348
Weight (kg) 75.1 – 17.6 71.5 – 14.3 0.063
Duration of diabetes
(years)
16.6 – 8.4 17.7 – 9.1 0.473
SMBG (per week) 26.5 – 8.8 25.3 – 8.8 0.388
Insulin (IU/kg/day) 0.7 – 0.2 0.8 – 0.2 0.001
Severe hypoglycemiaa 0.4 – 1.0 0.2 – 0.7 0.170
Knowledge (DKQ2) 24.7 – 4.1 24.8 – 4.5 0.926
Adherence (SCI-R) (%) 64.2 – 10.8 60.0 – 11.7 0.024
Quality of life (EuroQol) 66.4 – 18.2 63.0 – 18.5 0.266
Clarke ‡ 4R (%) 28.9 18.7 0.240
Data are mean – SD values.
aLast 6 months.
BMI, body mass index; DKQ2, Diabetes Knowledge Question-
naire; EuroQoL, European Quality of Life; HbA1c, glycated
hemoglobin; SCI-R, Diabetes Self-Care Inventory—Revised;
SMBG, self-monitoring of blood glucose.






















































visits (V2–V6) was 20 min (range, 14–22 min), versus 117 min
(range, 112–119 min) in the CG (including travel time). The
total time of the program in the CG was 823 – 645 min versus
353 – 222 min in the IG (P < 0.0001).
The percentages of unemployed, household workers, stu-
dents, noncertified service workers, certified workers, bach-
elor’s degrees, or other in the CG were 6.2%, 4.5%, 21.5%,
15.4%, 27.7%, 23.0%, and 1.5%, respectively, with similar
data in the IG (3.8%, 3.8%, 18.9%, 13.2%, 28.3%, 26.4%,
and 5.7%). Consequently, according to the salaries of the
Spanish population, the mean estimated cost of the total
clinical visits for patient was 38–116e in the IG and 90–270e
in the CG. The mean transportation cost was 6.3 – 5.2e in the
IG and 32.1 – 30.0e in the CG (P < 0.0001). The cost of the
modem and cable was 10e per month and patient.
The diabetes team costs in the length of appointments of
the total program were lower in the IG (288 – 105 min vs.
232 – 89 min; P < 0.001), with means of 185.6e and 144e,
respectively.
In relation to diabetes management, during the follow-up
only two patients in the CG needed an extra visit because of
sustained hyperglycemia. The number of telephone consul-
tations per patient during the study was 0.54 in the IG and
0.30 in the CG.
Clinical evolution
At the end of the study we observed a similar reduction of
HbA1c levels in both groups: IG, 9.2 – 1.5% (77.0 –
17.0 mmol/mol) versus 8.7 – 1.5% (71.6 – 17.0 mmol/mol)
(P < 0.001); CG, 9.2 – 0.9% (77.0 – 10.0 mmol/mol) versus
8.6 – 0.9% (70.5 – 10.0 mmol/mol) (P < 0.001). Eight patients
in the IG and six patients in the CG achieved HbA1c £ 7.5%.
Only one patient in the CG achieved a level of HbA1c < 7%.
No patient presented with ketoacidosis during the study. The
numbers of severe and mild hypoglycemic episodes were
similar in both groups. Mild hypoglycemia increased
slightly during the study (Table 2). We found a significant
increase in the knowledge test Diabetes Knowledge Ques-
tionnaire scores and in the adherence to self-care in both
groups. After 6 months of follow-up we did not observe
differences in the IG in relation to quality of life, whereas
improvement was observed in two scales of the Diabetes
Quality of Life (Satisfaction and Diabetes Worry) in the CG
(Table 2).
There was a tendency to increase the number of self-
monitoring of blood glucose tests per week, both in the IG
(V1 vs. V7, 25.8 – 8.5 vs. 28.5 – 7.9; P = 0.133) and in the CG
(V1 vs. V7, 26.3 – 7.7 vs. 28.8 – 7.1; P = 0.006).
Discussion
To our knowledge this is the first prospective, randomized
controlled study to evaluate the cost of telematic care as a
replacement to face-to-face outpatient appointments in a
specifically designed intensive follow-up program in poorly
controlled type 1 diabetes patients. The application of this
telematic tool for intensive monitoring of these patients is
less costly and more efficient than on-site visits. After a 6-
month follow-up, the results related to improvement in
metabolic control were within the range compared with pa-
tients following on-site visits.
FIG. 1. Study flowchart.






















































The most relevant finding in this study was the time saved by
the telematic care users. Accordingly, the patients in the IG
spent an average of 6 h to complete the follow-up (including
five telematic and two hospital visits), whereas those in the CG
required an average of 14 h to complete the face-to-face follow-
up. An average of approximately 20% less time was spent by
the diabetes team in the total follow-up of the IG compared
with the CG. In addition to the time saved, subjects in the IG
also spent less money on transportation than those in the CG.
From a clinical point of view we observed that the use of the
telematic system was as useful as face-to-face visits in im-
proving metabolic control (similar HbA1c reduction in both
groups, similar number of hypoglycemic events) in a group of
patients with chronic bad control, mainly because of poor self-
management refractory to previous attempts to improve met-
abolic control. The aim of our therapeutic program in these
patients, in which both groups received enhanced care com-
pared with what is standardly provided in Spain, was to im-
prove the knowledge and skills related to self-management.28
In this respect, it is important to point out that our telematic
intervention showed a similar positive impact as the conven-
tional visits. In addition, as previously shown,7 we observed
that the adherence to self-care improved similarly in both
groups of patients. On the other hand, it could be speculated
that the loss of the conventional clinical visit, face-to-face with
a healthcare professional, could induce deterioration in the
patient’s quality of life. However, this was not the case in our
study, but rather the contrary was observed: patients became
somewhat empowered to manage their disease.
It is important to note that the total cost of both interven-
tions may be considered site-specific and that the generaliz-
ability of the results is limited. However, we believe this is
not the case in the present study for several reasons: first, this
was a multicenter clinical trial, including markedly different
centers in Spain, in very different cities and related cost of
living or availability of transportation (access to physician).
Second, costs are derived mainly from the time spent for the
visit, which may be different across different countries, but
the difference (statistically significant) remained stable and
constant. And lastly, a sensitivity analysis of all the cost
figures is not likely to show any relevant change in either the
results or the direction of the recommendation.
Our results agree with a previous report by Chase et al.17 in a
study also performed in patients with type 1 diabetes. Thus, this
trial clearly shows that telemedicine is effective and safe, less
expensive, and more efficient than on-site visits. There is limited
literature showing similar results.29,30 In fact, there is conflicting
evidence on the effectiveness of telemedicine.18,20,30,31 This,
however, may be due to incomplete implementation of
technological advances and to studies being undertaken with
a study period of an insufficient length to allow adequate
evaluation. The population included in our trial mimics the
‘‘real world’’ population, and it is generally accepted that the
participation in any clinical trial could improve metabolic
control by the effect of more frequentation. Nonetheless, in
the present study, we found similar improvements in a par-
tially uncontrolled blinded population, thereby reinforcing
the contention of a sustained effect of telemedicine across
time beyond the trial bias.
This study has some limitations. The first is the relatively
high number of dropouts in the IG due to technical problems.
This is a key point in order to implement these technologies in
clinical practice. Robust, easy systems are necessary. Second,
there may be some biases in the costs evaluation. The results
could be underestimated in relation to the ability of the pa-
tients to recall indirect costs derived from the visits (for ex-
ample, substitutions in their usual activity) and because the
cost attributable to accompanying persons was not quantified.
Table 2. Clinical Evolution (Results per-Protocol)
Control group Intervention group
n Visit 1 Visit 7 P value n Visit 1 Visit 7 P value
HbA1c 64 54
% 9.2 – 0.9 8.6 – 0.9 < 0.001 9.2 – 1.5 8.7 – 1.5 < 0.001
mmol/mol 77.0 – 10.0 70.5 – 10.0 77.0 – 17.0 71.6 – 17.0
Weight (kg) 64 71.8 – 14.4 73.0 – 14.9 0.002 53 75.5 – 17.6 75.8 – 17.7 0.453
BMI (kg/m2) 64 25.2 – 4.5 25.7 – 4.7 < 0.001 53 26.0 – 4.4 26.2 – 4.4 0.539
Insulin (U/kg/day) 63 0.6 – 0.2 0.7 – 0.3 0.508 53 0.9 – 0.3 0.9 – 0.3 0.411
Mild hypoglycemiaa 58 4.1 – 3.8 7.6 – 4.3 < 0.001 48 4.0 – 3.5 6.7 – 5.6 < 0.001
Severe hypoglycemiab 55 0.5 – 1.1 0.2 – 0.1 0.002 46 0.2 – 0.6 0.2 – 1.2 0.733
Knowledge (DKQ2)c 63 24.8 – 4.4 26.8 – 4.0 < 0.001 51 24.5 – 4.6 26.1 – 4.6 0.008
Adherence (SCI-R) (%)c 63 64.1 – 10.7 69.8 – 9.6 < 0.001 53 61.3 – 12.0 66.1 – 11.0 0.003
Quality of life (EuroQol)c 50 67.1 – 17.7 66.9 – 17.4 0.922 50 65.0 – 18.8 69.9 – 18.7 0.904
DQoLc 63 53
Satisfaction 35.6 – 10.0 33.2 – 9.0 0.021 35.1 – 10.4 34.5 – 8.9 0.561
Impact 33.9 – 8.4 33.5 – 8.4 0.554 34.1 – 8.4 32.3 – 7.8 0.061
Social Worry 14.3 – 5.3 14.2 – 4.9 0.928 13.7 – 5.0 13.6 – 4.6 0.868
Diabetes Worry 9.8 – 3.3 9.0 – 3.0 0.011 8.9 – 3.0 8.8 – 3.0 0.742
Clarke ‡ 4R (%)c 63 30.8 23.8 0.317 53 17.3 17.0 1.000




BMI, body mass index; DKQ2, Diabetes Knowledge Questionnaire; DQoL, Diabetes Quality of Life; EuroQoL, European Quality of
Life; HbA1c, glycated hemoglobin; SCI-R, Diabetes Self-Care Inventory—Revised; SMBG, self-monitoring of blood glucose.






















































To the contrary, we did not consider indirect hospital costs in
the face-to-face visits. Moreover, there may be some costs
unaccounted for such as the Internet connection, point of
measurement costs, etc., which may be considered as negli-
gible and with no analysis of the sensitivity of the cost var-
iables. Furthermore, we have provided costs in both time and
economic counter value, as we acknowledge there may be
disparities in the costing figures when the project is to be
applied in other constituencies (circumstances), although, as
previously discussed, we would not anticipate any difference
in the results.
And finally, we must acknowledge that in this trial we have
accounted for the costs of the MGD interface. However,
when patients were enrolled, they were asked to have an
Internet connection, and currently several self-monitoring of
blood glucose meters come with features that enable a similar
control free of charge.
In conclusion, the application of telemedicine applied to
control subjects with poorly controlled type 1 diabetes is a
valid strategy, providing results similar to those of on-site
visits on comparison of the improvement in glycemic control,
the acquisition of knowledge, quality of life, and treatment
adherence. This approach also significantly reduces the time
and the costs involved, especially for the patients.
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